Index · 1 ranked
Funds Tracking the NYSE FactSet Global Genomics and Immuno Biopharma
Ranked by expense ratio, lowest first.
Data as of May 31, 2026 ·How this data is built
As of May 31, 2026, FundVersus ranks 1 funds tracking the NYSE FactSet Global Genomics and Immuno Biopharma by expense ratio. The lowest is iShares Genomics Immunology and Healthcare ETF (IDNA) at 0.47%. The median is 0.47%; weighted by assets, 0.47%.
Facts from SEC filings. Not investment advice.
The ranking
Only the stated measure sets the order. Expense ratios from prospectuses; net assets and returns from Form N-PORT.
| # | Fund | Expense ratio | Net assets | 1-year return | |
|---|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETFIDNA · ETF · Health Care | 0.47% | $160M | +41.47% |
Questions
How is this list ranked?
Ranked by expense ratio, lowest first. It includes funds tracking the NYSE FactSet Global Genomics and Immuno Biopharma with a current SEC filing and enough data for a FundVersus page. The ranking uses one stated measure and is not a recommendation.
Which has the lowest expense ratio?
iShares Genomics Immunology and Healthcare ETF (IDNA), at 0.47% as of May 31, 2026.
How much money is in these funds?
The 1 funds on this list reported $160M in combined net assets on their latest filings.